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Abstract: 
Hepatitis B virus (HBV) infection is a leading source of liver diseases such as hepatitis, cirrhosis and hepatocellular carcinoma. In 
this study, we use computation methods in order to improve our understanding of the complex interactions that occur between 
molecules related to Hepatitis B virus (HBV). Due to the complexity of the disease and the numerous molecular players involved, 
we devised a method to construct a systemic network of interactions of the processes ongoing in patients affected by HBV. The 
network is based on high-throughput data, refined semi-automatically with carefully curated literature-based information. We find 
that some nodes in the network that prove to be topologically important, in particular HBx is also known to be important target 
protein used for the treatment of HBV. Therefore, HBx protein is the preferential choice for inhibition to stop the proteolytic 
processing. Hence, the 3D structure of HBx protein was downloaded from PDB. Ligands for the active site were designed using 
LIGBUILDER. The HBx protein’s active site was explored to find out the critical interactions pattern for inhibitor binding using 
molecular docking methodology using AUTODOCK Vina. It should be noted that these predicted data should be validated using 
suitable assays for further consideration. 
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Background: 
The World Health Organization (WHO) estimates that there are 
currently 400 million individuals worldwide who are 
chronically infected, of whom 100 million eventually will die [1] 
with the hepatitis B virus (HBV), it is critically important to 
understand how persistent HBV infection is maintained and 
linked to chronic hepatitis, cirrhosis, and development of liver 
cancer (hepatocellular carcinoma [HCC]) [2]. HBV is a member 
of the Hepadnaviridae  family of viruses. The natural host for 
HBV is humans [2], although similar viruses have been isolated 
from apes, woodchucks (woodchuck hepatitis virus [WHV]), 
squirrels (ground squirrel hepatitis virus [GSHV]), herons 
(heron hepatitis B virus), ducks (duck hepatitis B virus), geese 
(goose hepatitis B virus), and cranes (crane hepatitis B virus). 
The hepadnavirus genome is a partially double-stranded 
circular DNA structure that is encapsidated within the 
enveloped viral particle [3]. Upon infection of hepatocytes, viral 
DNA is transported to the nucleus, where it is converted to a 
covalently closed, circular, double-stranded DNA (cccDNA). 
The cccDNA is essentially an episome that does not replicate 
but functions solely as the template for all viral transcription 
[3]. The HBV genome is highly compact, such that over 50% of 
the coding capacity lies in at least two open reading frames. 
Genomic and subgenomic viral transcripts, all of which utilize 
the same polyadenylation signal, are all transcribed from 
cccDNA. Viral mRNAs encode the viral core (HBcAg), envelope 
(HBsAgs), polymerase/reverse-transcriptase (pol), and HBx 
polypeptides. The largest HBV transcript, the pregenomic RNA 
(pgRNA), is also the template for viral replication and is reverse 
transcribed by the viral pol, similar to the replication of BIOINFORMATION  open access 
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retroviruses  [4].  H o w e v e r,  i n  c o n t ra s t  t o t h a t  o f  c on v e n t i on a l  
retroviruses, reversetranscribed HBV DNA is not integrated 
into the host cell genome as a requisite step in the viral life 
cycle. Instead, an intermediate in the replication reaction, a 
partially double-stranded viral DNA genome, is encapsidated 
within the mature viral particle. Viral pgRNA is encapsidated 
in cytoplasmic viral particles comprised of core protein, known 
as core particles, within which reverse transcription and DNA 
replication occur. As the virus replicates, it buds into the 
endoplasmic reticulum by envelopment within the viral HBsAg 
proteins and is eventually secreted from the infected cell [2]. 
While all hepadnaviruses can establish persistent infections in 
their respective hosts, only chronic infection by mammalian 
hepadnaviruses is associated with significant development of 
HCC [2]. As avian viruses either lack the HBx gene or, at best, 
encode a highly divergent form, the potential role of HBx in the 
development of HCC in mammals has been an area of intense 
interest for research [5]. 
 
Role of hepatitis B virus proteins: 
In addition to the integration of viral genome into host DNA, 
another direct role of HBV in hepatocarcinogenesis involves the 
long-term expression of viral proteins such as X protein (HBx) 
[2, 6]. This is supported by the observation that in a large 
portion of HCCs, viral DNA sequences encoding these proteins 
are found to be integrated in the host genome [8]. Hepatitis B 
virus has a unique fourth ORF coding for a protein known as 
HBx  [9-11].
 
The HBX gene is well conserved among the 
mammalian hepadnaviruses and codes for a 16.5 kDa protein, 
which has been detected in both the nucleus and the cytoplasm. 
HBX mRNA (0.7 kb) has been detected in infected liver, but the 
protein has not been easy to detect. HBX gene has been shown 
to be essential for the establishment of HBV infection in vivo 
[7]. HBx likely binds directly to the transcription factor CREB 
and possibly to transcription factors TFIIB, TFIIH, and the RNA 
polymerase II-associated protein RPB5, but the latter might 
interact with HBx via secondary interactions with CREB. HBx-
CREB transcription complexes have been shown to stimulate 
transcription. HBx is thought to act on the mitochondria, 
causing calcium release, in turn activating the Pyk2/FAK and 
Src kinase families, leading to stimulation of a variety of 
cytoplasmic signal transduction pathways. Interaction of HBx 
w i t h  t h e  U V - D D B  p r o t e i n s  ( 1  a n d / o r  2 )  i s  i m p l i c a t e d  i n  
stimulation of viral replication. HBx interaction with the 
proteasome is also reported to stimulate HBV replication [2].  
 
HBx is a promiscuous transactivator, it activates a variety of 
viral and cellular promoters in diverse cell types, and it has 
been shown to transactivate several viral and cellular targets. It 
can activate p53 but can also influence a variety of signal 
transduction pathways like MAPK/ERK, protein kinase B 
(PKB), PKC, SAPK/JNK, Phosphatidylinositol 3-Kinase (PI-3-K) 
and janus kinase (JAK)/STAT kinase pathways within the cell.
 
HBx up regulates the activity of a number of transcription 
factors. However, the majority of HBx is localized to the 
cytoplasm where it interacts with and stimulates protein 
kinases. It can also localize to the mitochondrion where it acts 
as an adaptor or kinase activator to influence signal 
transduction pathways [7, 12]. HBx can bind to C-terminus of 
p53 forming a proteinprotein complex and inactivating many 
functions of p53, including apoptosis. HBx sequester p53 in the 
cytoplasm and prevents it from entering the nucleus. HBV 
protects itself from apoptotic death through an HBx-P13K-AKT-
Bad pathway and by inactivating caspase 3 activity that is 
partially p53 independent in hepatocytes.The proapoptotic 
action of HBx overcomes the inhibitory effect of Bcl-2 against 
Fas cytotoxicity. HBx also up regulates surviving expression, an 
inhibitor of apoptosis (IAP) family. HBx also promotes the 
apoptosis of liver cells by upregulating the expressions of 
Fas/Fasl, Bax/Bcl-2, Bcl-xL, and c-myc in a dose dependant 
manner. Thus HBx has function in both pro-apoptosis and anti 
apoptosis pathways dependent on different cell settings. 
Increased anti-apoptosis and decreased pro-apoptosis in HCC is 
an important mechanism [13]. The integrated HBx is frequently 
mutated and has a diminished ability to function as a 
transcriptional cotransactivator and to activate the nuclear 
factor kappa-B (NF-κB) pathway [7].  
 
In this study we present the first step towards an integrated 
construction of Molecular-Interaction Network pathways in 
Hepatitis B virus. Our focus is on the interactions of the protein 
HBx, as this protein HBx play a central role in regulation of 
hepatitis, cirrhosis, and development of hepatocellular 
carcinoma. This HBx protein is involved in the cell cycle 
regulation, apoptosis, signalling, transcriptional regulation, 
encoding of cytoskeleton, cell adhesion molecules, oncogenes 
and tumour suppressor genes. Therefore, understanding the 
integrated function of this protein is of great importance in 
development of effective therapies for these diseases. In the 
s e c o n d  s t e p s  o f  t h i s  s t u d y  w e  d e s i g n e d  a n  i n h i b i t o r  w h i c h  
showed inhibitory activity towards Hepatitis B virus HBx 
protein. The binding interactions between this inhibitor and 
HBx protein were studied by docking methods using AutoDock 
vina software. The aim of this study was to get a better ligand 
that could inhibit polyprotein processing of HBV, and to better 
understand the interactions between the inhibitor and the 
enzyme’s binding sites via computational docking methods. We 
hope, this Drug will get success to clear out all the phases of 
clinical trial and it will be effective drug in the cure HBV’s 
diseases. 
 
Methodology: 
Data: 
Using the search terms ‘Hepatitis B virus AND hepatitis b virus 
disease AND hepatitis b virus x protein’, an intensive literature 
search of scientific papers was done in order to identify genes, 
proteins and small molecules that relate to HBV. Finally, peer-
reviewed articles had been enrolled and combined with data 
publicly available in the KEGG database 
‘http://www.genome.jp/kegg/’ in order to further identify 
proteins involved in HBV and to aid reconstruction of 
pathways.  
 
Construction of the Molecular-Interaction Network: 
Using the data obtained, the general molecular interaction 
network was created in PathVisio v2.0.11. Initially, connections 
were built among all the molecules (proteins, genes, DNAs, 
simple molecules, ions and antisense RNA) presented in the 
literature studied. In some cases, detailed regulatory 
relationships between different molecules, such as activation, 
inhibition and phosphorylation were available, enabling the re-
construction of part of the HBV map. In the case where BIOINFORMATION  open access 
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molecules were identified in the literature, but their interactions 
not identified, we searched the KEGG PATHWAY database for 
missing connections. Where no interaction information was 
available from either the literature or KEGG database, the 
molecules were excluded from the map. Each entity in the 
network is annotated with a complete list of interactions in 
which it participates, and PMIDs supporting those interactions 
(Figure 1). Entities are also linked to Uniprot, NCBI and KEGG 
pages. From this Molecular-Interaction Network of HBV, HBx 
protein was taken for further in silico structure based drug 
designing study. 
 
 
Figure 1: Molecular-interaction map for Hepatitis B virus. 
 
HBx as a Target Protein: 
Out of all the entries for HBx protein from RCSB protein data 
bank, HBx protein 3I7H was taken for docking analysis. The 
active site residues were found to be 88- ILPKVLHKRTLGLS -
101.  
 
Generating novel ligands: 
The structure of the fragment, i.e. the “seed molecule” was 
revealed on the basis of previous studies of available inhibitors 
for HBx protein [1]. The fragment “(2S, 3R)-2-(hydroxymethyl) 
tetrahydrofuran-3-ol” was identified on the basis of “Lipinski's 
Rule of Five” and may therefore represent suitable starting 
point for evolution of good quality lead compounds. The 
docking analysis of “(2S, 3R)-2-(hydroxymethyl) 
tetrahydrofuran-3-ol” compound with HBx protein was carried 
out by HEX (http://hex.loria.fr/) docking software with 
default parameters. The conformation of the pre-placed “seed” 
ensuring the binding affinity decides the manner that ligands 
would be grown with Ligbuilder software. Novel ligands had 
been developed with Ligbuilder 
(http://mdl.ipc.pku.edu.cn/drug_design/work/ligbuilder.htm
l) v1.2 software. We developed 100 novel ligands for the 
inhibitory site in HBx protein. 
 
Virtual screening: 
Virtual screening, an in silico tool for drug discovery, has been 
widely used for lead identification in drug discovery programs. 
Out of 100 novel ligands generated, 10 ligands were selected on 
the basis of maximum binding affinity measured in kcal/mol. 
The selected 10 ligands were then analyzed for drug- relevant 
properties based on “Lipinski’s rule of five” and other drug like 
properties of valid structures using OSIRIS Property Explorer BIOINFORMATION  open access 
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(http://www.organic-chemistry.org/prog/peo/), Molsoft: 
Drug- Likeness and molecular property explorer 
(http://www.molsoft.com/mprop/). On the basis of binding 
affinity and drug like properties, one ligand that passed all of 
the screening tests was taken for further molecular docking 
study. 
 
Protein-ligand docking: 
The docking of ligands to the catalytic triad of HBx protein for 
HBV was performed using AutoDock Vina software. Docking 
was performed to obtain a population of possible 
conformations and orientations for the ligand at the binding 
site. Using the software, polar hydrogen atoms were added to 
the HBx protein and its nonpolar hydrogen atoms were 
merged. All bonds of ligands were set to be rotatable. All 
calculations for protein-fixed ligand-flexible docking were done 
using the Lamarckian Genetic Algorithm (LGA) method. The 
grid box with a dimension of 40 x 40 x 40 points was used 
around the catalytic triad to cover the entire enzyme binding 
site and accommodate ligands to move freely. The best 
conformation was chosen with the lowest docked energy, after 
the docking search was completed. The interactions of complex 
HBx protein-ligand conformations, including hydrogen bonds 
and the bond lengths were analyzed using Accelrys DS 
Visualizer software (http://accelrys.com). 
 
Molecular descriptors calculation: 
Quantitative structure-activity relationships (QSARs) correlate 
the response with molecular properties of compounds under 
interest. Any compound to be considered as a lead must 
possess acceptable scores for all of the descriptors. The OSIRIS 
Property Explorer (http://www.organic-
chemistry.org/prog/peo/), Molsoft: Drug-Likeness and 
molecular property explorer 
(http://www.molsoft.com/mprop/), and Molinspiration 
property explorer 
(http://www.molinspiration.com/cgibin/properties/) were 
used to calculate 18 descriptors- logP, solubility, drug likeliness, 
polar surface area, molecular weight, number of atoms, number 
of rotatable bonds, volume, drug score and number of 
violations to violations to assure  its drug-confirm behavior. 
 
Results and Discussion: 
Construction of the Molecular-Interaction Network: 
We find that some nodes in the network that prove to be 
topologically important, in particular HBx, Polymerase, HBsAg 
and HBcAg & HBeAg, are also known to be associated with 
drugs used for the treatment of Hepatitis B. Importantly, based 
on topological consideration, we are also able to suggest HBx as 
a novel potentially relevant target protein for the diagnosis or 
treatment of Hepatitis B. This type of finding proves the 
potential of in silico analyses able to produce highly refined 
hypotheses, based on vast experimental data, to be tested 
further and more efficiently. As research on Hepatitis B is 
ongoing, the present map is in fieri, despite being -at the 
moment- a reflection of the state of the art.  
 
HBx as a Target Protein: 
Via the pathway analysis, we also found that HBx is associated 
with a number of pathways, for instance, the cell cycle 
regulation, apoptosis, signalling, transcriptional regulation, 
encoding of cytoskeleton, cell adhesion molecules, oncogenes 
and tumour suppressor genes. So it is reasonable here to 
suggest that HBx could be an interesting candidate as potential 
new drug target for the treatment of Hepatitis B. This is 
consistent with the recommendation in [13]. 
 
Protein-ligand docking: 
The Protein-ligand interaction plays a significant role in 
structure based drug designing. Overall, the best confirmation 
showed that the free energy of binding (ΔGbind kacl/mol) for 
the designed ligand were good and represented in Table 2 and 
Figure 2A & B. The negative and low value of ΔGbind indicates 
strong favorable bonds between HBx protein and the novel 
ligand indicating that the ligand was in its most favourable 
conformations. The information about the number of hydrogen 
bonds formed and catalytic site residues involved in protein-
ligand complex are shown in Table and figure. 
 
 
Figure 2: Docking representations of HBX protein. (A) Docked 
Ligand inside the pocket of HBX protein. (B)  H-Bond 
interactions (blue dashed line) of the docked ligand with Active 
site residues. 
 
Molecular descriptors calculation: 
The further descriptor analysis and the toxicity prediction 
(Tables 1 see supplementary material) helped in the 
identification of the better inhibitor. Drug Score and the Drug-
Likeness are the two properties that are important for 
considering a compound to become a successful drug. Novel 
ligand had a drug score of 0.29 and drug likeness property 
score of 0.49. The molecular weight of novel ligand was 398.619 
g/mol between the preferred ranges of molecular weight for 
drug likeness property. From Table 1 novel ligand was the 
compound that had the acceptable range (green colors) for 
toxicity risk. These values were also taken into account to 
decide the best inhibitor. Thus, novel ligand was the best drug 
candidate and also found to possess better global binding 
affinity score. 
 
Conclusion: 
In this study we have successfully reconstructed and analysed a 
systemic network of interactions of the processes on-going in 
patients affected by Hepatitis B. Through the topological 
analysis of this Hepatitis B network, HBX has been identified to 
be a hub of pathway. In this study, we designed a novel ligand 
against HBX protein of HBV.  The molecular docking was 
applied to explore the binding mechanism and studies on the 
novel ligand against the HBX protein showed that the free 
binding energy for the inhibitor was small, indicating that the BIOINFORMATION  open access 
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ligand binds favorably to the binding site. The ligand was 
observed as the best inhibitor candidate, which may be 
considered as a potential ligand for treatment of diseases 
caused by HBV. Using a combination of virtual screening, and 
molecular docking, we successfully identified putative novel 
inhibitor, which can be further evaluated by in vitro and in vivo 
biological tests. 
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Supplementary material: 
 
Table 1: Molecular descriptors value for novel inhibitor. 
Descriptors  Lead compound Scores 
LogP 4.65 
Solubility -4.48 
Molecular weight  398.619 
TPSA 69.918 
n Atoms  28 
n Violations  1 
N Rotatable bonds  12 
Volume 426.017 
Number of stereo centers  5 
Number of HBA  4 
Number of HBD  3 
Mutagenic Green 
Tumorigenic Green 
Irritant Green 
Reproductive Effective  Green 
Drug likeness  0.49 
Drug score  0.29 
Molecular formula  C24H46O4 
 
Table 2: The number of Hydrogen bonds formed and the catalytic site residues involved in protein-ligand complex along with 
binding affinity. 
Virus 
protein 
No. of Hydrogen 
bonds  
Catalytic site residue(s) in 
Hydrogen bonding 
Binding Affinity 
(Kcal/mol) 
HBX 1,2  Leu93,Thr97  -7.2 
 
 
 
 